Search in:

mAbs Volume 3, 2011 - Issue 2

Submit an article Journal homepage

Open access

1,383

Views

CrossRef citations to date

Altmetric

Meeting Report

IBC's 21^st Annual Antibody Engineering and 8^th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society

December 5–9, 2010, San Diego, CA USA

Samantha O Arnett Department of Immunology & Microbial Science and IAVI Neutralizing Antibody Center; The Scripps Research Institute; La Jolla, CA USA

Jean-Luc Teillaud Cordeliers Research Center/INSERM U.872; Paris Descartes University and Pierre & Marie Curie University (UPMC); Paris

Thierry Wurch Centre d'Immunologie Pierre FABRE; Saint Julien en Genevois; France

Janice M ReichertmAbs; Landes Bioscience; Austin, TXCorrespondence[email protected]

Cameron Dunlop Department of Immunology & Microbial Science and IAVI Neutralizing Antibody Center; The Scripps Research Institute; La Jolla, CA USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA USA

Michael Huber Department of Immunology & Microbial Science and IAVI Neutralizing Antibody Center; The Scripps Research Institute; La Jolla, CA USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA USA

Pages 133-152 | Received 23 Jan 2011, Accepted 23 Jan 2011, Published online: 01 Mar 2011

Cite this article
https://doi.org/10.4161/mabs.3.2.14939

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68:4821 - 4828
PubMed Web of Science ®Google Scholar
Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343 - 346
PubMed Web of Science ®Google Scholar
Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101 - 104
PubMed Web of Science ®Google Scholar
Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J Virol 2002; 76:7306 - 7321
PubMed Web of Science ®Google Scholar
Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892 - 10905
PubMed Web of Science ®Google Scholar
Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79:1252 - 1261
PubMed Web of Science ®Google Scholar
Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285 - 289
PubMed Web of Science ®Google Scholar
Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, et al. Lethal antibody enhacement of dengue disease in mice is prevented by Fc modification. PLoS Pathogens 2010; 6:1000790
PubMed Web of Science ®Google Scholar
Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function of therapeutic monoclonal antibodies against dengue virus type 2. J Virology 2010; 84:9227 - 9239
PubMed Web of Science ®Google Scholar
Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:3942
PubMed Web of Science ®Google Scholar
Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246 - 251
PubMed Web of Science ®Google Scholar
Reichert JM. Antibody-based therapeutics to watch in 2011. mAbs 2011; 3:76 - 99
PubMed Web of Science ®Google Scholar
Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 2008; 105:5986 - 5991
PubMed Web of Science ®Google Scholar
Heinis C, Rutherford T, Freund S, Winter G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat Chem Biol 2009; 5:502 - 507
PubMed Web of Science ®Google Scholar

References

Mazor Y, van Blarcom T, Mabry R, Iverson BL, Georgiou G. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 2007; 25:563 - 565
PubMed Web of Science ®Google Scholar
Li H, d'Anjou M. Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol 2009; 20:678 - 684
PubMed Web of Science ®Google Scholar
Potgieter TI, Cukan M, Drummond JE, Houston-Cummings NR, Jiang Y, Li F, et al. Production of monoclonal antibodies by glycoengineered Pichia pastoris. J Biotechnol 2009; 139:318 - 325
PubMed Web of Science ®Google Scholar
Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24:210 - 215
PubMed Web of Science ®Google Scholar
Abes R, Gelizé E, Fidman WH, Teillaud JL. Long-lasting anti-tumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116:926 - 934
PubMed Web of Science ®Google Scholar
de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. CLL cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. British J Hæmatol 2008; 140:635 - 643
PubMed Web of Science ®Google Scholar
Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Kunkhouser R, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100 - 106
PubMed Web of Science ®Google Scholar
Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, mMxfield LF, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nature Med 2010; 16:319 - 323
PubMed Web of Science ®Google Scholar
Santra S, Liao HX, Zhang R, Muldoon M, Wartson S, Fischer W, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nature Med 2010; 16:324 - 328
PubMed Web of Science ®Google Scholar
Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 2001; 61:4750 - 4755
PubMed Web of Science ®Google Scholar
Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009; 24:155 - 161
PubMed Web of Science ®Google Scholar
Kwon MH, Lee MS, Kim KH, Park S, Shin HJ, Jang YJ, et al. Production and characterization of an anti-idiotypic single chain Fv that recognizes an anti-DNA antibody. Immunol Invest 2002; 31:205 - 218
PubMed Web of Science ®Google Scholar
Kim YR, Kim JS, Lee SH, Lee WR, Sohn JN, Chung YC, et al. Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity. J Biol Chem 2006; 281:15287 - 15295
PubMed Web of Science ®Google Scholar
Kim DS, Lee SH, Kim JS, Lee SC, Kwon MH, Kim YS. Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting. Biochem Biophys Res Commun 2009; 379:314 - 318
PubMed Web of Science ®Google Scholar
Jang JY, Jeong JG, Jun HR, Lee SC, Kim JS, Kim YS, et al. A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity. Cell Mol Life Sci 2009; 66:1985 - 1997
PubMed Web of Science ®Google Scholar
Lee WR, Jang JY, Kim JS, Kwon MH, Kim YS. Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies. Nucleic Acids Research 2010; 38:1596 - 1609
PubMed Web of Science ®Google Scholar
Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767 - 774
PubMed Web of Science ®Google Scholar
Boyman O, Surh CD, Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006; 6:1323 - 1331
PubMed Web of Science ®Google Scholar
Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206:751 - 760
PubMed Web of Science ®Google Scholar
Letourneau S, van Leeuwen EM, Krieg C, Martin C, Pantaleo G, Sprent J, et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci USA 2010; 107:2171 - 2176
PubMed Web of Science ®Google Scholar
Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70:588 - 597
PubMed Web of Science ®Google Scholar
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415 - 1425
PubMed Web of Science ®Google Scholar
Ridgway JBB, Presta LG, Carter P. “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617 - 621
PubMedGoogle Scholar
Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345 - 1352
PubMed Web of Science ®Google Scholar
Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 2010; 54:4137 - 4142
PubMed Web of Science ®Google Scholar
Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 2010; 201:1481 - 1487
PubMed Web of Science ®Google Scholar
Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure 2010; 18:332 - 342
PubMed Web of Science ®Google Scholar
Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, et al. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008; 325:882 - 892
PubMed Web of Science ®Google Scholar
Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010; 12:204
PubMed Web of Science ®Google Scholar
Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, et al. Immunologic, clinical and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72:396 - 401
PubMed Web of Science ®Google Scholar
Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?. Arch Neurol 2010; 67:923 - 930
PubMed Web of Science ®Google Scholar
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010; 68:409 - 411
PubMed Web of Science ®Google Scholar

References

Ward ES, Ober RJ. Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol 2009; 103:77 - 115
PubMed Web of Science ®Google Scholar
Pérez Montoyo H, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA 2009; 106:2788 - 2793
PubMed Web of Science ®Google Scholar
Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 2009; 10:600 - 614
PubMed Web of Science ®Google Scholar
Walker A, Dunlevy G, Rycroft D, Topley P, Holt LJ, Herbert T. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel 2010; 23:271 - 278
PubMed Web of Science ®Google Scholar
Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102:75 - 85
PubMed Web of Science ®Google Scholar
Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005; 11:7053 - 7063
Web of Science ®Google Scholar
Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010; 46:2926 - 2935
PubMed Web of Science ®Google Scholar
Dumelin CE, Trüssel S, Buller F, Trachsel E, Bootz F, Zhang Y, et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl 2008; 47:3196 - 3201
PubMed Web of Science ®Google Scholar
Trüssel S, Dumelin C, Frey K, Villa A, Buller F, Neri D. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem 2009; 20:2286 - 2292
PubMed Web of Science ®Google Scholar
Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006; 66:3271 - 3277
PubMed Web of Science ®Google Scholar
Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008; 97:4696 - 4740
PubMed Web of Science ®Google Scholar
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006; 66:6732 - 6740
PubMed Web of Science ®Google Scholar
Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, et al. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol 2007; 44:3777 - 3788
PubMed Web of Science ®Google Scholar
Vigor KL, Kyrtatos PG, Minogue S, Al-Jamal KT, Kogelberg H, Tolner B, et al. Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 2010; 31:1307 - 1315
PubMed Web of Science ®Google Scholar
Cheng WW, Allen TM. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv 2010; 7:461 - 478
PubMed Web of Science ®Google Scholar
Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 2008; 126:50 - 58
PubMed Web of Science ®Google Scholar
Laginha KM, Moase EH, Yu N, Huang A, Allen TM. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J Drug Target 2008; 16:605 - 610
PubMed Web of Science ®Google Scholar
O'Reilly MK, Tian H, Paulson JC. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J Immunol 2011; 186:1554 - 1563
PubMed Web of Science ®Google Scholar
Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 2010; 115:4778 - 4786
PubMed Web of Science ®Google Scholar
Yallapu MM, Jaggi M, Chauhan SC. Scope of nanotechnology in ovarian cancer therapeutics. J Ovarian Res 2010; 3:19
PubMed Web of Science ®Google Scholar
Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010; 351:19 - 29
PubMed Web of Science ®Google Scholar
van der Horst EH, Murgia M, Treder M, Ullrich A. Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int J Cancer 2005; 115:519 - 527
PubMed Web of Science ®Google Scholar
Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008; 68:8039 - 8048
PubMed Web of Science ®Google Scholar
Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 2010; 70:7221 - 7231
PubMed Web of Science ®Google Scholar
Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101:1045 - 1052
PubMed Web of Science ®Google Scholar
Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003; 63:5480 - 5489
PubMed Web of Science ®Google Scholar
Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112:4170 - 4177
PubMed Web of Science ®Google Scholar
Beers SA. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115:5191 - 5201
PubMed Web of Science ®Google Scholar
Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173:4699 - 4707
PubMed Web of Science ®Google Scholar
Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512 - 520
PubMed Web of Science ®Google Scholar
European Medicines Agency. Draft Guideline on similar biological medicinal products containing monoclonal antibodies 2010; 11 18 www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099361.pdf
Google Scholar

References

d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009; 33:465 - 473
PubMed Web of Science ®Google Scholar
Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38 - 48
PubMed Web of Science ®Google Scholar
Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum 2010; 62:1933 - 1943
PubMed Web of Science ®Google Scholar
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399:436 - 449
PubMed Web of Science ®Google Scholar
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147 - 1157
PubMed Web of Science ®Google Scholar
Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429 - 440
PubMed Web of Science ®Google Scholar
Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76 - 99
PubMed Web of Science ®Google Scholar
Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010; 10:489 - 491
PubMed Web of Science ®Google Scholar
Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate Trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398 - 405
PubMed Web of Science ®Google Scholar
Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. mAbs 2009; 1:128 - 141
PubMed Web of Science ®Google Scholar
Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010; 40:167 - 181
PubMed Web of Science ®Google Scholar
Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, et al. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel 2010; 23:243 - 249
PubMed Web of Science ®Google Scholar
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 4402
PubMed Web of Science ®Google Scholar
Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, et al. Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. Mol Cancer Ther 2011; 10:178 - 185
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

IBC's 21^st Annual Antibody Engineering and 8^th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society

December 5–9, 2010, San Diego, CA USA

References

References

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society

December 5–9, 2010, San Diego, CA USA

References

References

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

IBC's 21^st Annual Antibody Engineering and 8^th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society